Search in the Abstract Database

Search Abstracts 2015

* = Presenting author

P243 Prevalence of extraintestinal manifestations in paediatric patients with Inflammatory Bowel Disease: Results from the Swiss IBD Cohort Study

S. Vavricka*1, R. Rechner2, N. Fournier3, 4, G. Rogler1, P. Michetti5, V. Pittet3, E. Safroneeva6, A. Straumann7, C. Braegger8, A. Nydegger9, A. Schoepfer10

1University of Zurich, Gastroenterology and Hepatology, Zurich, Switzerland, 2University Hospital Zurich, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Zurich, Switzerland, 3Institute of Social and Preventive Medicine, Healthcare Evaluation Unit, Lausanne, Switzerland, 4University of Lausanne, IUMSP, Lausanne, Switzerland, 5Crohn and Colitis Center Clinique La Source , Gastroenterology, Lausanne, Switzerland, 6University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland, 7University of Basel, Gastroenterology and Hepatology, Basel, Switzerland, 8University of Zurich, Pediatric Gastroenterology, Zurich, Switzerland, 9University of Lausanne, Pediatric Gastroenterology, Lausanne, Switzerland, 10Centre Hospitalier Universitaire Vaudois, Gastroenterology and Hepatology, Lausanne, Switzerland


There is a paucity of data from large cohort studies on the prevalence and type of extraintestinal manifestations in pediatric patients with Crohn's disease (CD) and ulcerative colitis (UC). We aimed to assess the prevalence and type of EIM in pediatric patients with inflammatory bowel disease (IBD).


Data from patients enrolled in the Pediatric Swiss IBD Cohort Study (P-SIBDCS) were analyzed. Since 2008 the P-SIBDCS collects data on patients aged 2-17 from hospitals and private practices across Switzerland. Results of continuous data are reported as median and interquartile range.


A total of 266 pediatric IBD patients were recruited (146 [54.9%] with CD, 63% boys, median [interquartile] age at diagnosis 12 [9.9-13.6] years, median age at enrollment 13.6 [11.7-15.3] years, median disease duration 3.3 [1.6-4.9] years, and 120 [45.1%] with UC, 47.5% boys, median age at diagnosis 11.5 [8.2-13.6] years, median age at enrollment 13.5 [10.9-15.3] years, median disease duration 3.2 [1.6-5.7] years. A total of 90 patients (33.8%) suffered from one to a maximum of three EIM during their disease course (74/90 patients [82.2%] had one EIM, 14/90 patients [15.6%] had two EIM, and 2/90 patients [2.2%] suffered from three EIM. EIM were more frequently observed in CD patients (61/146, 41.8%) when compared to UC patients (29/120, 242%, p < 0.001). The following types of EIM were observed: 37/266 (13.9%) peripheral arthritis / arthralgia (17.8% in CD vs. 9.2% in UC); 5/266 (1.9%) uveitis / iritis (2.7% in CD vs. 0.8% in UC; 26/266 (9.8%) oral aphthous ulcers (12.3% in CD vs. 6.7% in UC); 2/266 (0.8%) ankylosing spondylitis (0.7% in CD vs. 0.9% in UC); 5/266 (1.9%) erythema nodosum (2.7% in CD vs. 0.8% in UC); 2/266 (0.8%) pyoderma gangrenosum (0.7% in CD vs. 0.8% in UC).


EIM appear in pediatric IBD patients in similar prevalence when compared to the adult population. As a general rule, EIM are more frequently observed in pediatric CD patients when compared to pediatric UC patients. The most frequent EIM are peripheral arthritis / arthralgia, followed by oral aphthous ulcers.